Double announcement day for Bittensor's best subnet: 1) expansion into North America, the world's largest AI market, furthering SN44 adoption and 2) conviction locking ONE MILLION dollars of owner alpha.
LET'S GO $TAO 🚀
Good morning Paris.
This week at @proofoftalk for sn44:
Monday: Strategic announcement and conviction lock.
Tuesday: @tm0klc takes the stage on why an open visual intelligence layer matters for the world.
Wednesday: @MaxScore sits with institutional stakeholders on subnet growth and distribution.
Thursday: Tim, Max and @arnod3f get back on the road deploying @manakoai across more @Avia_France petrol stations.
Friday: Well, let’s see.
.@NBA, if you can describe what kind of AI you need,
our network will build it for you.
Not in years, not in months, but in weeks.
It will be more efficient, more affordable, more open than legacy tech and continuously optimised and improved.
Decentralised AI is the real world champion, dear Adam Silver.
@MsMelChen The solution is to rally around open source.
That's the only way to compete with a superpower technology network effect if you are not a superpower yourself. And it's the only way to bring the rest of the world along on the same team as you.
Open source.
$TAO holders. This one is personal.
I live with an autoimmune disease. I know what the standard of care looks like. I know what corticosteroids do to your body when you have to rely on them for years.
So when @metanova_labs, SN68, announced its new IL-6 target, I paid attention and locked in to what they are doing.
Autoimmune disease affects roughly 50 million Americans and around 8% of the global population.
Lupus. Rheumatoid arthritis. Crohn’s. MS. Psoriasis. Hashimoto’s.
For many patients, long-term steroid use is still the fallback. The side effects are so brutal.
Osteoporosis. Cataracts. Glaucoma. Metabolic damage. Adrenal suppression. Weight gain. Mood instability.
IL-6 is one of the major inflammatory signals in the body. If you can target it cleanly, you can potentially treat inflammation without destroying everything else around it.
That is why IL-6 inhibitors are already a multi-billion dollar market.
Actemra. Kevzara. Treatments that can run tens of thousands per patient per year.
Now, NOVA is bringing that into Bittensor.
Their last nanobody target was PD-L1 for cancer immunotherapy. They received 8,446 unique nanobody submissions from an open decentralized competition.
Now, they are moving to IL-6 in partnership with Yalotein, with top submissions eligible for wet lab validation.
That is the important part.
This is not just AI generating molecules for a dashboard.
This is a decentralized virtual screening flowing toward real biologics development.
And if it wasn't for biologics, my quality of life would be so different now!
NOVA is also making the chemical search competition more exploration focused. Molecules that are too chemically similar will be rejected.
That matters because in drug discovery, making 1,000 versions of the same idea is easy.
Finding genuinely different scaffolds that actually work is the hard part.
That is where real breakthroughs come from.
This is why NOVA is different from most AI drug discovery.
NOVA is hundreds of miners competing in parallel, paid in $TAO, ranked by results, and pushing the best candidates toward wet lab testing.
Cancer, on the one hand.
Inflammation on the next.
What I am watching now:
How many IL-6 submissions come in compared to the 8,446 from PD-L1.
Whether the new exploration rules increase true chemical diversity.
Most importantly, what happens in wet lab validation with Yalotein.
Because that is where decentralized AI either proves itself in physical reality or it does not.
The people who need better autoimmune treatments are not thinking about crypto.
They are in waiting rooms or emergency rooms.
They are trying to work through pain.
They are choosing between rent and the medication.
They are hoping for something better, period.
If decentralized incentive driven discovery can shave years off the timeline or help lower the cost of better therapies, the impact is not just measured in token price.
It is measured in lives and quality of life itself.
That is why I care about this network.
It's not just a chart.
The work.
NOVA is one subnet. There are many more. Each one is writing its own version of this incredible mission while the market argues about everything else.
I will be watching IL-6 closely.
Personally and otherwise.
$TAO
If you just got laid off from Meta and you build in the field of vision AI or AI powered medicine discovery, look into @webuildscore and @metanova_labs. $TAO
I just got laid off from Meta.
Obviously it sucks to lose the income. But between the never-ending layoffs, stack ranking, etc., I'm good. Pretty convinced that when I look back at this moment a few years into the future, I'll be grateful it happened.
There's a lot I want to say here, but I'll save that for another day. Either way it's been a privilege to have been a part of the ride. On to the next adventure.
I have an autoimmune condition and can totally relate. I can't be more proud to stake to @metanova_labs $TAO SN68. Imagine if together we fund discoveries of some amazing medications to improve the lives of many millions of people. 👇🏾
New NOVA nanobody target is live: IL-6 (Interleukin-6)
IL-6 is one of the central signaling proteins behind inflammation and immune regulation.
When dysregulated, it has been implicated in:
- autoimmune disorders
- chronic inflammation
- neuroinflammation
- blood-brain barrier disruption
Making it a highly relevant target for inflammatory, neurological, and immune-related diseases.
The IL-6 inhibitor market is already worth billions annually, with drugs targeting this pathway generating multi-billion dollar revenues across autoimmune and inflammatory indications, validating both the biological and commercial importance of the target.
Miners across NOVA will now compete to design nanobodies targeting IL-6 in an open, adversarial discovery environment.
Top submissions may also be selected for wet lab validation through our partnership with @Yalotein, helping close the loop between decentralized virtual screening and real-world biologics development.
#Bittensor #SN68 #DrugDiscovery #Biotech #Nanobodies #DeSci
Smart cities won’t run on spreadsheets. They’ll run on intelligent networks like Bittensor. Most people still think of housing like a static asset.
@zipcodenetwork (foremerly RESI) is turning it into programmable infrastructure. Feels like exciting things are underway👇👀 $TAO
Introducing https://t.co/aBk9elR898
The network for real estate intelligence & finance.
First, we built the world's most accurate property valuation model.
Next, we open Real Estate lending to everyone.
From login to liquid in minutes.